

**MEETING REPORT OF THE
ORDINARY AND EXTRAORDINARY GENERAL MEETING
ON MAY 27, 2026**

EUOAPI's ordinary and extraordinary General Meeting has been held on Wednesday 27, 2026 at 10:00.m., at Théâtre Traversière – 15 bis, rue Traversière – 75012 Paris, under the presidency of Emmanuel Blin.

All resolutions submitted to the shareholders for approval were adopted, including:

- the unconsolidated and consolidated financial statements for the financial year ended December 31, 2024 as well as the allocation of the loss to the “carried forward account”;
- the 2025 remuneration policy for members of the Board of Directors, for the Chairs and Chief Executive Officers;
- as well as the fixed, variable and exceptional items comprising the total compensation and benefits of any kind paid during the financial year ended December 31, 2024 or awarded in respect of the same financial year to the Chairs and Chief Executive Officers;
- the renewal of the terms of office of the members of the Board of Directors; and
- the authorization to purchase the Company's own shares.

Emmanuel Blin, Chair of the Board of Directors, opened the session with an overview of the Company during the financial year ended December 31, 2025. He highlighted the Company's cost discipline in a challenging business environment, notably marked by lower sales to Sanofi due to an unfavorable comparison base, while emphasizing growth in opiates activities, progress in profitability and the strengthening of the Group's financial discipline. He also reviewed the significant progress achieved under the FOCUS-27 plan, including the increased share of differentiated products in sales, the advancement of the CDMO portfolio, the divestment of the Haverhill site and the continuation of targeted industrial investments.

Olivier Falut, Chief Financial Officer, then presented the 2025 consolidated financial results, characterized by an improvement in Core EBITDA, positive cash generation, disciplined working capital management and a reduction in industrial investments while maintaining priority on growth and performance projects.

David Seignolle, Chief Executive Officer, presented the 2026 outlook and the update on the FOCUS-27 plan. He reiterated that the Group continues to execute its transformation in order to strengthen its long-term competitiveness despite a market environment still marked by significant competitive pressure. He also outlined the Group's priorities for 2026, including the continued optimization of the product portfolio, additional cost reduction initiatives, strict working capital management and the acceleration of the strategic plan implementation.

Emmanuel Blin then presented the governance and the work of the Board of Directors and its Committees during 2025. Elizabeth Bastoni, Chair of the Nomination and Remuneration Committee, subsequently presented the remuneration policy of the executive and non-executive officers.

The auditors presented their report and Sébastien Hache, secretary of the meeting, presented the resolutions submitted to the shareholders for approval.

Written questions were submitted and answered during the meeting, before the opening of the Q&A sessions, which are available on the website of the Company:

<https://www.euroapi.com/en/investors/regulatory-information/annual-general-meetings/2026-annual-general-meeting>

Main topics addressed during the Q&A session:

- Remuneration policy
- European sovereignty
- Commercial policy and new products
- Company valuation
- Impact of the Middle East conflict
- Asian imports
- Competitiveness plan
- Divestments

Finally, the 25 resolutions submitted to the shareholders for approval were approved. The results are available on the website of the Company:

<https://www.euroapi.com/en/investors/regulatory-information/annual-general-meetings/2026-annual-general-meeting>

The session was adjourned at 12:05 p.m.